Genetic Variants Affecting the Clinical Severity of Beta Thalassemia

Sponsor
Nanfang Hospital of Southern Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04918056
Collaborator
303rd Hospital of the People's Liberation Army (Other), Liuzhou Municipal Maternity and Child Healthcare Hospital (Other), Zhuhai Municipal Maternal and Child Healthcare Hospital (Other), Dong Guan Maternal and Child Health Hospital (Other)
1,300
1
77.7
16.7

Study Details

Study Description

Brief Summary

β-thalassemia is one of the most common single gene disorder in Southern China. The phenotypic severity of beta thalassemia widely varies from mild to severe forms. Patients with the same beta thalassemia genotype show wide phenotypic variability that ranges from moderate to severe disease due to various genetic modifiers of disease severity. The aim of this study is to looking for the genetic factors which could affect the severity of beta thalassemia.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Hematological Analysis and Genetical Analysis

Detailed Description

The understanding of the genotype-phenotype correlation is a very important issue to the precise diagnosis of beta thalassemia. However, the genotype-phenotype correlation of Beta thalassemia is so complex that the pathogenesis of some patients remains uncertain and cannot be explained by known mechanisms. The study of the role of the genetic variants in modulating beta thalassemia phenotype could brought us considerable novel and interesting information in this area. We will collecting more than 1000 beta thalassemia patients , analyzing their clinical data and genome data, and association study will be conducted to screen the positive genetic variants which exert a significant effect on both the HbF levels and onset ages of beta thalassemia patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1300 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Screening and Identification of Genetic Modifiers Which Affecting the Phenotype Severity of Beta Thalassemia Patients
Actual Study Start Date :
Jan 1, 2017
Anticipated Primary Completion Date :
Jan 11, 2022
Anticipated Study Completion Date :
Jun 25, 2023

Arms and Interventions

Arm Intervention/Treatment
beta thalassemia patients

Diagnostic Test: Hematological Analysis and Genetical Analysis
Hematological Analysis: Hematological parameters were determined with an automated hematology analyzer (Sysmex, Japan), and hemoglobin analysis was performed with either high-performance liquid chromatography (Bio-Rad, USA) or capillary electrophoresis (Sebia, France and Helena, USA). Genetical Analysis: Genomic DNA was extracted from peripheral blood (PB) by using a standard phenol/chloroform method. The genotypes of samples are analyzed by NGS assay.

Outcome Measures

Primary Outcome Measures

  1. Genetic variants which could influence the phenotype of beta thalassemia [1 year]

    Identified a group of single-nucleotide polymorphisms (SNPs) that contribute to β-thalassemia

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosed with β-thalassemia
Exclusion Criteria:
  • Iron Deficiency Anemia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Southern Medical University Guangzhou Guangdong China 510515

Sponsors and Collaborators

  • Nanfang Hospital of Southern Medical University
  • 303rd Hospital of the People's Liberation Army
  • Liuzhou Municipal Maternity and Child Healthcare Hospital
  • Zhuhai Municipal Maternal and Child Healthcare Hospital
  • Dong Guan Maternal and Child Health Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nanfang Hospital of Southern Medical University
ClinicalTrials.gov Identifier:
NCT04918056
Other Study ID Numbers:
  • PDD-Beta thalassemia
First Posted:
Jun 8, 2021
Last Update Posted:
Jun 11, 2021
Last Verified:
May 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Nanfang Hospital of Southern Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 11, 2021